Recombinant IV-type humanized collagen as well as preparation and application thereof

By employing recombinant expression and purification techniques, the problems of low yield and high cost of recombinant human collagen have been solved, resulting in highly efficient expression and purification of recombinant type IV humanized collagen, which exhibits significant tissue repair and skin regeneration regulatory functions and is suitable for industrial production.

CN121270682APending Publication Date: 2026-01-06SHENZHEN CHENGMEI BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511407852.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-09-29
Publication Date
2026-01-06

AI Technical Summary

Technical Problem

Existing recombinant human collagen has low yield, high cost, and incomplete modification, making it difficult to meet the needs of industrial production and functionality, especially in tissue engineering and implantable medical products where there is a risk of immune rejection and viral infection.

Method used

Recombinant type IV humanized collagen was expressed and purified via recombination, containing a specific amino acid sequence or its variants, and fused with a purification tag and a leader. Pichia pastoris was used as the host cell for efficient expression and purification, and the protein was purified using chromatography.

Benefits of technology

It achieves efficient expression and purification of recombinant type IV humanized collagen, retains its biological activity, promotes the secretion and expression of type III collagen by human skin fibroblasts, has the potential to regulate tissue repair and skin regeneration, and is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121270682A_ABST
    Figure CN121270682A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicine and functional protein engineering, and particularly relates to recombinant IV type humanized collagen as well as preparation and application thereof. The invention provides a novel human-derived IV-type collagen functional fragment, which not only can be efficiently expressed and purified in a recombination mode, but also shows the capability of remarkably promoting human skin fibroblasts (HSF) to secrete and express III-type collagen in functional verification, and has definite tissue repair and skin regeneration regulation potential. In-vitro cell experiments prove that the recombinant collagen fragment provided by the invention can promote adhesion, migration and proliferation of fibroblasts or keratinocytes, and has the functions of repairing, regenerating and supporting a cell microenvironment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedicine and functional protein engineering technology, specifically relating to a recombinant type IV humanized collagen and its preparation and application. Background Technology

[0002] Collagen is the most abundant structural protein in mammals, accounting for approximately 25%–35% of total protein. It exists widely in tissues such as skin, bones, blood vessels, cornea, tendons, and internal organs in the form of unbranched fibrils, and is an important component of the extracellular matrix, playing a crucial role in maintaining tissue morphology, structural stability, and tissue repair. Traditional collagen is mostly extracted from animal tissues through acid, alkali, or enzymatic hydrolysis; however, these products often lose their natural biological activity due to structural damage, making it difficult to meet the functional requirements for medical applications. Furthermore, animal-derived collagen carries potential risks of viral infection and immune rejection, limiting its application in tissue engineering and implantable medical products.

[0003] With the development of synthetic biology and recombinant protein expression technology, the expression of humanized collagen has become a research hotspot. However, conventionally recombinantly expressed humanized collagen often suffers from problems such as low yield, high cost, and incomplete modification, making industrial production impossible. In particular, the development of short fragments for functional research and medical materials is still in the initial exploratory stage.

[0004] Type IV collagen is an important structural component of the basement membrane, playing crucial biological functions in cell adhesion, differentiation, migration, and signal transduction. As a core structural component of the basement membrane, type IV collagen exists as an insoluble three-dimensional network structure and participates in important physiological processes such as maintaining tissue boundaries and regulating cell behavior. Studies have found that proteolysis of type IV collagen mediated by matrix metalloproteinases (MMP-2, -9, -14) can release biologically active functional fragments, some of which originate from the NC1 domain at the α-terminus of its soluble fragments. These soluble fragments possess unique biological functions, regulating the adhesion, migration, and proliferation of endothelial cells and fibroblasts, and playing a role in angiogenesis and signaling pathway regulation.

[0005] Although some recombinant fragments of type IV collagen have been developed for basic research or material function verification, their functions are still mostly limited to general cell compatibility. Summary of the Invention

[0006] The purpose of this invention is to provide a recombinant type IV humanized collagen and its preparation and application. It can not only be efficiently expressed and purified through recombinant methods while retaining its biological activity at the cellular level, but also shows a significant ability to promote the secretion and expression of type III collagen by human skin fibroblasts (HSF) in functional verification, and has clear potential for tissue repair and skin regeneration regulation.

[0007] Therefore, the present invention provides the following technical solution.

[0008] A first aspect of the present invention provides a recombinant type IV humanized collagen comprising n repeating units, said repeating units being directly or via linkers, said repeating units comprising:

[0009] (1) The amino acid sequence shown in SEQ ID NO.2;

[0010] (2) An amino acid sequence obtained by substituting, deleting, or inserting one or more amino acids based on SEQ ID NO. 2; or

[0011] (2) An amino acid sequence having at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO.2;

[0012] Preferably, n is an integer from 1 to 20.

[0013] In a preferred embodiment of the present invention, the collagen comprises:

[0014] (1) The amino acid sequence shown in SEQ ID NO.1; or

[0015] (2) An amino acid sequence having at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO. 1; or

[0016] (3) An amino acid sequence obtained by substituting, deleting or inserting one or more amino acids based on SEQ ID NO.1.

[0017] A second aspect of the present invention provides a fusion protein comprising recombinant humanized type IV collagen as described above and a purified tag and / or precursor;

[0018] Preferably, the purification tag is selected from His tag, GST tag, MBP tag, SUMO tag or NusA tag.

[0019] A third aspect of the present invention provides a polynucleotide encoding the recombinant type IV humanized collagen or fusion protein as described above;

[0020] Preferably, the polynucleotide comprises the nucleotide sequence shown in SEQ ID NO.5 or a degenerate sequence thereof.

[0021] A fourth aspect of the present invention provides a carrier comprising the polynucleotides as described above;

[0022] Preferably, the carrier is an expression carrier;

[0023] Preferably, the vector includes a control element operatively linked to a polynucleotide;

[0024] Preferably, the control element is selected from promoters, terminators, and / or enhancers.

[0025] A fifth aspect of the invention provides a host cell comprising the polynucleotides as described above, or a vector;

[0026] Preferably, the host cell is selected from bacteria, fungi, or animal cells;

[0027] Preferably, the bacteria include Escherichia coli;

[0028] Preferably, the fungus includes yeast, such as Pichia pastoris.

[0029] A sixth aspect of the present invention provides a method for producing recombinant type IV humanized collagen or fusion protein as described above, comprising the following steps:

[0030] (1) Culture the host cells as described above under suitable culture conditions;

[0031] (2) Harvesting host cells and / or culture medium containing recombinant type IV humanized collagen or fusion protein; and optionally...

[0032] (3) Purify the recombinant type IV humanized collagen or fusion protein.

[0033] A seventh aspect of the invention provides a composition comprising one or more of the recombinant type IV humanized collagen, fusion protein, polynucleotide, vector, and host cell as described above.

[0034] In a preferred embodiment of the present invention, the composition is selected from one or more of the following: biological dressings, human biomimetic materials, plastic and cosmetic materials, organoid culture materials, cardiovascular stent materials, coating materials, tissue injection filling materials, ophthalmic materials, obstetric and gynecological biomaterials, nerve repair and regeneration materials, liver tissue materials and vascular repair and regeneration materials, 3D printed artificial organ biomaterials, cosmetic raw materials, pharmaceutical excipients and food additives.

[0035] Preferably, the composition is a surface composition, an injectable composition, or an oral composition;

[0036] Preferably, the composition is a composition in the form of a solution, lyophilized powder, gel, sponge, or fiber.

[0037] The eighth aspect of the present invention provides the use of the recombinant type IV humanized collagen, fusion protein, polynucleotide, carrier and host cell as described above in the preparation of one or more of the following: bio-dressings, human biomimetic materials, plastic and cosmetic materials, organoid culture materials, cardiovascular stent materials, coating materials, tissue injection filling materials, ophthalmic materials, obstetric and gynecological biomaterials, nerve repair and regeneration materials, chronic wound repair materials, bone / cartilage regeneration materials, liver tissue materials and vascular repair and regeneration materials, 3D printed artificial organ biomaterials, cosmetic raw materials, pharmaceutical excipients and food additives.

[0038] A ninth aspect of the present invention provides a method for promoting cell proliferation, migration or adhesion, comprising the step of contacting the recombinant type IV humanized collagen, fusion protein, polynucleotide, carrier, host cell and / or composition as described above with the cells.

[0039] Preferably, the cell is an animal cell;

[0040] Preferably, the animal cell is a mammalian cell;

[0041] Preferably, the mammalian cell is a human cell;

[0042] Preferably, the promotion of cell proliferation, migration, or adhesion is carried out in vitro.

[0043] The tenth aspect of the present invention provides a method for performing cosmetic surgery, tissue injection filling, ophthalmic treatment, nerve repair or vascular repair on a subject in need, comprising administering the subject recombinant type IV humanized collagen as described above.

[0044] Preferably, the administration is oral or injectable.

[0045] Preferably, the subject is a human being.

[0046] The eleventh aspect of the present invention provides the use of the recombinant type IV humanized collagen as described above in the preparation of a medicament for diseases or conditions related to type IV collagen deficiency.

[0047] By employing the above technical solution, the present invention has at least the following advantages:

[0048] The recombinant type IV collagen of this invention is derived from natural human type IV collagen and will not cause immune rejection or allergic reactions when applied to the human body.

[0049] The novel human type IV collagen functional fragment provided by this invention can not only be efficiently expressed and purified through recombinant methods, but also demonstrates a significant ability to promote the secretion and expression of type III collagen by human skin fibroblasts (HSF) in functional verification, exhibiting clear potential for tissue repair and skin regeneration regulation. In vitro cell experiments have verified that the recombinant collagen fragment provided by this invention can promote the adhesion, migration, and proliferation of fibroblasts or keratinocytes, possessing functions of repairing, regenerating, and supporting the cellular microenvironment.

[0050] The recombinant type IV collagen of the present invention is suitable for preparation by biosynthesis, has a large expression level and is suitable for subsequent purification, has high production efficiency and no pollution, and has good prospects for industrial production.

[0051] The above description is merely an overview of the technical solution of the present invention. In order to better understand the technical means of the present invention and to implement it in accordance with the contents of the specification, the preferred embodiments of the present invention are described in detail below. Attached Figure Description

[0052] Figure 1 The recombinant plasmid map of recombinant type IV collagen is shown;

[0053] Figure 2 The images show PAGE images of recombinant type IV collagen expression during the induced culture process; where A is the PAGE image of C4-Y1; and B is the PAGE image of C4-Y2.

[0054] Figure 3 The PAGE images of purified recombinant type IV collagen are shown; where A is the PAGE image of C4-Y1; and B is the PAGE image of C4-Y2.

[0055] Figure 4 The Fourier transform infrared (FTIR) spectrum of recombinant type IV collagen C4-Y1 is shown.

[0056] Figure 5 This demonstrates the effect of recombinant type IV collagen C4-Y1 on cell migration;

[0057] Figure 6The effect of recombinant type IV collagen C4-Y1 on HSF cell proliferation was demonstrated;

[0058] Figure 7 This study demonstrates the effects of recombinant type IV collagen C4-Y1 on the secretion of Col I and Col III by HSF cells;

[0059] Figure 8 This study demonstrates the effect of recombinant type IV collagen C4-Y1 on ColIII expression and secretion in HSF cells;

[0060] Figure 9 The effects of recombinant type IV collagen C4-Y1 on the transcriptional levels of MMP-1 and ColIII in HSF cells were demonstrated. Detailed Implementation

[0061] To make the technical means, creative features, achieved objectives, and effects of this invention readily understandable, the technical solutions in the embodiments of this invention will be clearly and completely described below in conjunction with the embodiments of this invention. Obviously, the described embodiments are merely some embodiments of this invention, and not all embodiments. Based on the embodiments of this invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this invention.

[0062] Terminology Definition

[0063] As used in this article, "recombinant collagen" is a new type of biomaterial that uses cutting-edge structural biology, genetic engineering and other technologies to screen and prepare a gene encoding the functional region of human collagen specific type as a template, and obtains an amino acid sequence that is the same as or similar to that of human collagen.

[0064] As used herein, “recombinant humanized type IV collagen” refers to a recombinant protein consisting of or substantially consisting of sequences derived from human type IV collagen. In this context, recombinant humanized type IV collagen may consist of or substantially consist of fragments or multiple repeats of fragments derived from human type IV collagen.

[0065] As used herein, “one or more” can be any suitable integer. In the case of collagen mutations (e.g., substitution, deletion, insertion, or addition), “one or more” is a number readily determined by those skilled in the art, such as 190 and any integers and ranges therebetween, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, or 39, etc.

[0066] As used herein, the term “expression” includes any step involved in peptide production, including but not limited to: transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

[0067] As used herein, the term "vector" is a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector enables the expression of a protein encoded by the inserted polynucleotide, it is called an expression vector. Vectors can be introduced into host cells through transformation, transduction, or transfection, allowing the genetic material elements they carry to be expressed in the host cells. Vectors are well known to those skilled in the art and include, but are not limited to: plasmids; phage particles; Cos plasmids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC), or P1-derived artificial chromosomes (PAC); bacteriophages such as λ phage or M13 phage, and animal viruses. Vectors may contain various elements controlling expression, including but not limited to promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. Additionally, vectors may contain a replication initiation site. Vectors may contain the nucleic acids of this invention for introduction into cells for expression. Vectors may contain expression control elements operatively linked to the nucleic acids, such as promoters, terminators, and / or enhancers.

[0068] As used herein, the term "expression vector" refers to a straight or circular DNA molecule containing a polynucleotide encoding a polypeptide and operatively linked to a control sequence provided for its expression. In this paper, the expression vector is a Pichia pastoris expression vector.

[0069] As used herein, the term “recombinant expression vector” refers to a single-stranded or double-stranded nucleic acid molecule that is isolated from a naturally occurring gene, or modified to contain nucleic acid segments in a manner not normally found in nature, or is synthetic and contains one or more control sequences.

[0070] As used herein, the term "control sequence" refers to the nucleic acid sequence necessary for the expression of the polynucleotide encoding the mature polypeptide of the present invention. Each control sequence may be native (i.e., from the same gene) or exogenous (i.e., from different genes) for the polynucleotide encoding the polypeptide, or native or exogenous relative to each other. Such control sequences include, but are not limited to, leader sequences, polyadenylated sequences, propeptide sequences, promoters, signal peptide sequences, and transcription terminators. At a minimum, control sequences include promoters and transcription and translation termination signals. These control sequences may be provided with multiple linkers for the purpose of introducing specific restriction sites that facilitate the linking of control sequences to the coding region of the polynucleotide encoding the polypeptide.

[0071] As used herein, the term "host cell" refers to a cell into which nucleic acid molecules have been introduced using molecular biology techniques. These techniques include transfection with viral vectors, transformation with plasmid vectors, and accelerated introduction of naked DNA via electroporation, lipid transfection, and particle gun techniques. Host cells can be eukaryotic or prokaryotic cells. For example, eukaryotic cells include yeast cells, animal cells, and / or insect cells. Prokaryotic cells can be E. coli cells.

[0072] Recombinant type IV humanized collagen

[0073] This invention provides recombinant type IV humanized collagen. The recombinant type IV humanized collagen of this invention may comprise one or more repeating units, each repeating unit comprising:

[0074] (1) The amino acid sequence shown in SEQ ID NO.2;

[0075] (2) An amino acid sequence obtained by substituting, deleting, or inserting one or more amino acids based on SEQ ID NO. 2; or

[0076] (2) An amino acid sequence that has at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO.2.

[0077] In some implementations, the number of repeating units can be 1-20.

[0078] In some implementations, the number of repeating units is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0079] In some implementations, the repeating units are directly connected.

[0080] In some implementations, one or more amino acid residues are spaced between each repeating unit.

[0081] In some embodiments, the recombinant type IV humanized collagen of the present invention is synthetic or recombinantly expressed.

[0082] The recombinant type IV humanized collagen of the present invention comprises:

[0083] (1) The amino acid sequence shown in SEQ ID NO.1; or

[0084] (2) An amino acid sequence having at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO. 1; or

[0085] (3) An amino acid sequence obtained by substituting, deleting or inserting one or more amino acids based on SEQ ID NO.1.

[0086] Fusion protein

[0087] The present invention provides a fusion protein comprising recombinant humanized type IV collagen as described above and purified tags and / or precursors.

[0088] In some embodiments, the purification tag is selected from His tag, GST tag, MBP tag, SUMO tag, or NusA tag.

[0089] Recombinant type IV humanized collagen encodes nucleic acid

[0090] This invention provides a polynucleotide encoding recombinant humanized type IV collagen for expression.

[0091] In some embodiments, the polynucleotide is codon-optimized for the host cell in which it is expressed.

[0092] In some implementations, the polynucleotide encoding recombinant type IV humanized collagen can be operatively linked to expression control elements, such as promoters, terminators, and / or enhancers, to form a nucleic acid or expression cassette.

[0093] In some embodiments, the polynucleotide encoding recombinant type IV humanized collagen may also include nucleotides encoding purification tags, such as His tags, GST tags, MBP tags, SUMO tags, or NusA tags, or nucleotides encoding leader sequences to facilitate peptide purification or secretion.

[0094] In some embodiments, the polynucleotide comprises the nucleotide sequence shown in SEQ ID NO.3 or a degenerate sequence thereof.

[0095] host cells

[0096] The present invention also provides a host cell comprising the polynucleotides as described above, or a vector.

[0097] In some embodiments, the host cell is selected from bacteria, fungi, or animal cells.

[0098] In some embodiments, the bacteria include Escherichia coli.

[0099] In some embodiments, the fungus includes yeast, such as Pichia pastoris.

[0100] Compositions and their applications

[0101] This invention also provides compositions comprising recombinant type IV humanized collagen. These compositions include, but are not limited to, bio-dressings, biomimetic materials, plastic and cosmetic materials, organoid culture materials, cardiovascular stent materials, coating materials, tissue injection fillers, ophthalmic materials, obstetric and gynecological biomaterials, nerve repair and regeneration materials, chronic wound repair materials, bone / cartilage regeneration materials, liver tissue materials and vascular repair and regeneration materials, 3D-printed artificial organ biomaterials, cosmetic raw materials, pharmaceutical excipients, and food additives.

[0102] In some embodiments, the composition may be administered by means including, but not limited to, injection, topical application, or oral administration.

[0103] In some embodiments, the composition is a composition in the form of a solution, lyophilized powder, gel, sponge, or fiber.

[0104] Production of recombinant type IV humanized collagen

[0105] The present invention also provides the production of recombinant type IV humanized collagen, including functional region screening and strain construction, large-scale bio-fermentation, protein induction expression and purification steps.

[0106] In some embodiments, the functional region screening and strain construction steps include:

[0107] (1) Large-scale functional region screening to obtain the functional regions of the target gene;

[0108] (2) Insert the obtained target gene functional region into an expression vector (such as pCM01-COL4-1) to obtain a recombinant expression plasmid;

[0109] (3) The recombinant expression plasmid was transferred into competent Pichia pastoris cells (such as Pichia pastoris GS115) and positive Pichia pastoris genetically engineered bacteria were screened.

[0110] In some implementations, the large-scale biofermentation step includes:

[0111] The selected positive Pichia pastoris genetically engineered bacteria are added to a shake flask containing antibiotic stock solution and cultured on a shaker; preferably, the shaker culture conditions are 220 rpm and 30°C constant temperature.

[0112] In some implementations, the steps for inducing protein expression include:

[0113] (1) Set the induction stage temperature to 28℃;

[0114] (2) Add methanol to induce expression;

[0115] (3) The bacterial culture after induction expression was placed in a centrifuge bottle, centrifuged at 6000 rpm and 4℃ for 12 min, and then the bacterial cells were collected.

[0116] In some embodiments, the purification steps of type IV humanized collagen include:

[0117] (1) The first step of purification was performed using weak cation exchange chromatography. The chromatography packing material was Qianchun CM Purose 6FastFlow, which was loaded into a GE AKTA chromatography system.

[0118] (2) The eluent collected by ion exchange chromatography was purified by hydrophobic chromatography in the second step. The chromatography packing material was Phenyl Purose 6Fast Flow (High Sub), which was loaded into the GE AKTA chromatography system to obtain humanized type IV collagen.

[0119] The following embodiments are provided to illustrate the present invention. Those skilled in the art should understand that the embodiments are merely illustrative and not restrictive. The invention is limited only by the scope of the appended claims.

[0120] The following embodiments involve and mention:

[0121] 1. Experimental reagents

[0122] The reagents used in the experiment are shown in Table 1.

[0123] Table 1. Reagents and chemicals used in the experiment

[0124]

[0125]

[0126] 2. Experimental Instruments and Equipment The instruments and equipment used in the experiment are shown in Table 2.

[0127] Table 2. Instruments and equipment used in the experiment

[0128]

[0129]

[0130] 3. Strains used in the experiment

[0131] The bacterial strains used in the experiment are shown in Table 3.

[0132] Table 3. Strains used in the experiment

[0133]

[0134] 4. Carrier used in the experiment

[0135] The bacterial strains used in the experiment are shown in Table 4.

[0136] Table 4. Carriers used in the experiment

[0137]

[0138] Example 1: Construction and expression of recombinant type IV humanized collagen

[0139] 1. Sequence filtering

[0140] First, full-length collagen sequences from humans and other mammals were screened from the UniProt database (https: / / www.uniprot.org), covering common types such as COL4A1. After redundancy removal, a sliding window method was used to extract continuous fragments of length X (e.g., 27 or 30 amino acids) to construct a prediction dataset. Using a self-developed collagen Tm prediction model, these fragments were scored and screened, ultimately yielding several candidate fragments with significantly high thermal stability. Further fragment screening, combining literature and functional annotation, resulted in functionally relevant short fragments. All these sequences are clearly traceable natural sources in publicly available databases. In practical development, the collagen fragments described in this invention can be obtained through chemical or biosynthetic methods to further verify their stability, conformational ability, and application value.

[0141] The amino acid sequence of the obtained recombinant type IV humanized collagen C4-Y1 is shown in SEQ ID NO.1:

[0142] SEQ ID NO.1:

[0143] GPPGPPGYGPAGPIGDKGQAGFPGGPGSPGLPGPKGEPGKI

[0144] GPPGPPGYGPAGPIGDKGQAGFPGGPGSPGLPGPKGEPGKI

[0145] GPPGPPGYGPAGPIGDKGQAGFPGGPGSPGLPGPKGEPGKI

[0146] The sequence of its repeating units is shown in SEQ ID NO.2:

[0147] SEQ ID NO.2:

[0148] GPPGPPGYGPAGPIGDKGQAGFPGGPGSPGLPGPKGEPGKI

[0149] The amino acid sequence of the obtained recombinant type IV humanized collagen C4-Y2 is shown in SEQ ID NO.3:

[0150] SEQ ID NO.3:

[0151] GPPGPPGYPGPAGPIGDKGQAGFPGGPGSPGLPGPKGEPGKI

[0152] GPPGPPGYPGPAGPIGDKGQAGFPGGPGSPGLPGPKGEPGKI

[0153] GPPGPPGYPGPAGPIGDKGQAGFPGGPGSPGLPGPKGEPGKI

[0154] The sequence of its repeating units is shown in SEQ ID NO.4:

[0155] SEQ ID NO.4:

[0156] GPPGPPGYPGPAGPIGDKGQAGFPGGPGSPGLPGPKGEPGKI

[0157] 2. Construction of recombinant expression plasmids

[0158] The C4-Y1 or C4-Y2 base sequences of type IV collagen obtained through the above screening were then used to synthesize gene fragments by Anhui General Biotechnology Co., Ltd. The synthesized gene fragment (the nucleotide sequence of C4-Y1 is shown in SEQ ID NO.5) was inserted into the pCM01-COL4-1 vector via NotⅠ and CopⅠ restriction enzyme sites to obtain a recombinant plasmid of type IV collagen. The plasmid map is shown below. Figure 1 .

[0159] SEQ ID NO.5

[0160] ATGGGTCCTCCTGGTCCTCCTGGTTATCCTGGTCCTGCTGGTCCTATTGGTGATAAAGGTCAAGCTGGTTTTCCTGGTGGTCCTGGTTCTCCTGGTTTACCTGGTCCTAAAGGTGAACCTGGTAAAATTTAA

[0161] 3. Screening of recombinant expression plasmid-positive strains and high-density fermentation

[0162] 3.1 Preparation of culture medium and buffer solution

[0163] 3.1.1 The composition and preparation of the culture medium are shown in Table 5.

[0164] Table 5. Culture medium preparation

[0165]

[0166] 3.1.2 The composition and preparation of the buffer solution are shown in Table 6.

[0167] Table 6. Culture medium preparation

[0168]

[0169] 3.2 Preparation of Pichia pastoris competent cells

[0170] (1) The Pichia pastoris strain stored in a low-temperature freezer was activated using YPD plates and cultured until it reached a suitable size. (2) A single colony was picked and inoculated into 15 mL of YPD medium and cultured overnight until OD. 600 = Approximately 3. (3) Transfer approximately 10 mL of yeast culture to a 1 L Erlenmeyer flask containing 100 mL of YPD and incubate for approximately 5 hours. (4) When OD 600 When the temperature reaches approximately 2.0, stop the culture and place the two 50mL centrifuge tubes and the Erlenmeyer flask containing the bacterial solution on ice for a few minutes to pre-cool. Centrifuge at 4℃ and 4000g for 5 minutes, discard the supernatant, and resuspend the cells twice with approximately 30mL of pre-cooled ultrapure water under the same conditions. (5) Then resuspend the cells twice with 8mL of SB solution and culture at 30℃ and 220rpm for 30 minutes on a shaker. (6) After the culture is completed, centrifuge at low temperature, then discard the supernatant in the centrifuge tubes, and add 15mL of pre-cooled 1M Sorbitol to each of the two centrifuge tubes. Resuspend the cells twice under the same operation and conditions, and finally add 1mL of pre-cooled 1M Sorbitol to each to resuspend the cells to obtain a cell suspension. (7) Use a pipette to add 100μL of the obtained cell suspension to a pre-cooled EP tube. After the aliquots are completed, first freeze the obtained competent cells in a -20℃ freezer for several hours, and then store them in an ultra-low temperature freezer.

[0171] 3.3 Linearization of recombinant plasmids

[0172] The above recombinant plasmids were linearized by enzyme digestion using QuickCut Sal I at 37°C for 2 hours. The enzyme digestion system is shown in Table 7.

[0173] Table 7. Sal I Linearization System

[0174]

[0175] 3.4 Electroconversion of Pichia pastoris

[0176] (1) Take the appropriate number of electroporation cups, clean them thoroughly with ddH2O, then clean them thoroughly with 75% alcohol, place them in an oven to dry, open the lid after drying, and sterilize 1mL pipette, 1mL pipette tip, 200μL pipette, and 200μL pipette tip by UV irradiation for 30min. After completion, cover the electroporation cups and place them on ice to pre-cool for later use. (2) Take out competent cells and place them on ice to thaw naturally. Mix 100μL of competent cells and 10μL of linearized recombinant plasmid, and electroporate using the pic option on the electroporator. (3) Immediately after completion, add 600μL of premixed 1M Sorbital and YPD medium (ratio 1:1) to the ultra-clean workbench, mix gently, transfer to EP tubes, and incubate at 28℃ and 220rpm for 2h. (4) After centrifuging at 3000 rpm for 3 min, remove 500 μL of supernatant, gently aspirate and mix the remaining bacterial solution, spread it all onto MD screening plates, and incubate in an inverted incubator at 28℃ for about 36 to 48 h to grow more single colonies.

[0177] 3.5 Screening and Identification of Positive Transformants

[0178] 3.5.1 Transfer board

[0179] After 36-48 hours of growth, single colonies from the MD plates are streaked sequentially onto another MD or YPD plate with a grid drawn on it. The colonies are then marked to facilitate the preservation of the strain after successful screening and identification of positive clones.

[0180] 3.5.2 Methods for disrupting Pichia pastoris cell walls

[0181] (1) After 12 hours of transfer, pick a small number of single colonies from the YPD plate in a clean bench and transfer them to an eight-cell PCR tube, then cover it. (2) Place the picked bacterial culture in a microwave oven and heat on medium for 3-5 minutes, then immediately freeze in liquid nitrogen. After freezing, heat in a microwave oven on medium for 3-5 minutes. (3) Add 10-15 μL of double-distilled water to the bacterial cells to resuspend them, and obtain the Pichia pastoris culture after cell disruption, which can be used as a template.

[0182] 3.5.3 Pichia pastoris colony PCR

[0183] Using the Pichia pastoris culture after cell wall disruption as a template, the original plasmid of the gene (20 ng / μL) as a positive control template, and ddH2O as a negative control template, PCR amplification was performed according to the system in Table 8 and the procedure in Table 9. If the recombinant plasmid is successfully integrated into the genome, the expected size band can be obtained by PCR amplification.

[0184] Table 8. Pichia pastoris colony PCR reaction system

[0185]

[0186] Table 9. PCR program for Pichia pastoris colonies.

[0187]

[0188] Primer F: CGACAACTTGAGAAGATCAAAAAACAACTAATTATTCGAA (SEQ ID NO.6)

[0189] Primer R: CAGGCAAATGGCATTCTGACATCCTCTTGA (SEQ ID NO.7)

[0190] 3.5.4 24-well plate screening of recombinant type IV collagen

[0191] (1) Prepare sterilized 24-well plates in advance, and add 3 mL of BMGY medium to each well in a clean bench. (2) Pick single colonies that have successfully amplified the expected size band in the above PCR test and transfer them to a single well, label them, and incubate them at 28℃ and 220 rpm for 36-48 h. (3) After incubation, centrifuge at 1500 rpm for 15 min, remove the supernatant of the medium, add 1.5 mL of BMMY medium and 100% methanol to a final concentration of 1% (v / v) to each well to start methanol induction culture. Take samples every 24 h and add 100% methanol to a final concentration of 1% (depending on the situation, the initial detection of protein expression induction time is generally 1-3 days). Perform SDS-PAGE electrophoresis on the samples after 24 h of induction to detect whether there is protein expression of the expected size, and preserve the strains that express the target protein.

[0192] 3.5.5 Preservation of Positive Strains

[0193] Different recombinant expression strains were named CM001-C4-YXX-XX#. A certain amount of fresh positive single colonies from the plates were selected and placed into 1.5 mL EP tubes containing a 1:1 mixture of 50% glycerol and YPD. The tubes were thoroughly mixed by pipetting and stored at -80°C.

[0194] 3.6 High-density fermentation of recombinant type IV collagen

[0195] The selected strains GS115 / pCM01-COL4-1-C4-Y1-10# or GS115 / pCM01-COL4-1-C4-Y2-10# were subjected to high-density fermentation.

[0196] 3.6.1 Culture medium formulation

[0197] Seed culture medium (YPG): yeast extract 10 g / L, peptone 20 g / L, glycerol 20 g / L.

[0198] Fermentation medium: 1-9 g / L potassium dihydrogen phosphate, 0.1-5 g / L calcium sulfate dihydrate, 5-15 g / L magnesium sulfate heptahydrate, 5-15 g / L potassium sulfate, 10-80 g / L ammonium dihydrogen phosphate, 0.1-5 g / L potassium hydroxide, 5-25 g / L glycerol.

[0199] Feeding medium: 50% (w / v) glycerol.

[0200] Induction medium: 100% methanol (add 10 mL of PTM1 trace element solution per liter).

[0201] PTM1 trace element solution: CuSO4·5H2O 6g / L, MnSO4·H2O 3g / L, FeSO4·7H2O 65g / L, ZnSO4·7H2O 20g / L, CoCl2 0.2g / L, H3BO3 0.02g / L, NaMoO4·2H2O 0.2g / L, KI 0.1g / L, biotin 0.2g / L, H2SO4 5mL. Sterilize by filtration through a 0.22μm filter membrane and store at 4℃.

[0202] 3.6.2 Inoculation and Culture

[0203] (1) The fermenter was sterilized by steam high temperature and high pressure. First, an air sterilization was performed, and the temperature and pressure were maintained at 121℃ for 10 min. Before the actual sterilization, the pH electrode and dissolved oxygen (DO) electrode were calibrated. Then, 5L of the prepared fermentation medium (with 5mL of defoamer added during preparation) was added to the 10L fermenter, and the actual sterilization was performed, and the temperature and pressure were maintained at 121℃ for 30 min. After sterilization, the temperature was lowered to 30℃. The air flow meter was turned on to maintain the positive pressure in the tank at 0.05Mpa. (2) The Pichia pastoris engineered strain (GS115 / pCM01-COL4-1-C4-Y1-10# or GS115 / pCM01-COL4-1-C4-Y2-10#) stored in the ultra-low temperature freezer was inoculated into a medium containing 50mL of liquid YPG and cultured overnight in a constant temperature shaker at 30℃ and 220rpm to activate the cells. The primary seed culture was transferred to a medium containing 500 mL of LYPG at an inoculation rate of 5% (V / V) and cultured until the cell OD600 reached 6-8 to obtain the secondary seed culture. The secondary seed culture was added to the sterilized fermenter at an inoculation rate of 10% (V / V), and 20 mL of PTM1 trace element solution was added at the same time for batch fermentation. (3) The temperature for the cell glycerol growth and glycerol feeding stage was set at 30℃, and the pH was automatically adjusted to 4.5 by ammonia water; the temperature for the methanol induction stage was set at 28℃, and the pH was automatically adjusted to 5.0 by ammonia water. The DO was maintained in the range of 20%-50% by controlling the stirring speed of 200-500 rpm, the aeration rate of 2-6 L / min and the feeding rate. During the glycerol growth stage, when the DO continued to rise, it indicated that the glycerol in the medium was consumed. At this time, 1 L of 50% (W / V) glycerol was added. When the DO continued to rise again, and the cell wet weight reached 180 g / L-220 g / L, methanol induction was started. The feed rate was adjusted periodically to maintain DO (dissolved oxygen) within a cyclical fluctuation range of 10%-50%. After induction began, samples were taken every 12 hours, and protein expression was detected by SDS-PAGE. The SDS-PAGE results are shown below. Figure 2 .

[0204] like Figure 2 As shown, where, Figure 2 In A, lane M is the protein marker, and lanes 1-4 are the samples of C4-Y1 induced expression for 12h, 24h, 36h and 48h respectively. Figure 2 In section B, lane M is the protein marker, and lanes 1-4 are samples of C4-Y2 induced expression for 12h, 24h, 36h and 48h respectively.

[0205] 4. Purification of recombinant type IV collagen

[0206] After induction culture, the supernatant of the culture medium was collected by centrifugation. The first step of purification was performed using weak cation exchange chromatography with Qianchun CM Purose 6Fast Flow as the chromatographic packing material, loaded into a GE AKTA chromatography system. The column was equilibrated with pure water, and the supernatant of the fermentation broth was diluted to a conductivity of 3 mS / cm before loading. After loading, impurities were washed with pure water, followed by elution with phosphate buffer (25 mM, pH 7.40, hereinafter the same) containing 1 M NaCl, and the eluted proteins were collected. The eluent collected by ion exchange chromatography was then subjected to hydrophobic chromatography for the second step of purification with Qianchun Phenyl Purose 6Fast Flow (High Sub) as the chromatographic packing material, loaded into a GE AKTA chromatography system. The column was equilibrated with phosphate buffer containing 1 M ammonium sulfate, and ammonium sulfate was added to the CM eluent to a final concentration of 1 M / L before loading. After loading, impurities were washed with phosphate buffer containing 1 M ammonium sulfate, followed by elution with phosphate buffer, and the eluted proteins were collected. After concentration and fluid exchange via membrane encapsulation, recombinant type IV collagen stock solution was obtained. The protein molecular weight and purity were determined using SDS-PAGE. The results are shown below. Figure 3 .

[0207] like Figure 3 As shown, where, Figure 3 In A, lane M is the protein marker, and lanes 1-11 are samples purified from C4-Y1 of this application at different concentrations; Figure 3 In section B, lane M is the protein marker, and lanes 8-13 are samples purified from C4-Y2 of this application at different concentrations.

[0208] 5. Protein content detection

[0209] Protein content was determined using the Kjeldahl method. Specific operating procedures can be found in the Kjeldahl method instructions in the Chinese Pharmacopoeia. The calculation method is as follows:

[0210] Protein concentration = (Total nitrogen content - Non-protein nitrogen content) * Protein coefficient. The test results are shown in Table 10 below:

[0211] Table 10 Protein Content

[0212]

[0213] Example 2: Fourier transform infrared spectroscopy characterization of the structure of type IV collagen

[0214] This embodiment utilizes Fourier Transform Infrared Spectroscopy (FTIR) to characterize the structure of the recombinant collagen obtained in Example 1. Fourier Transform Infrared Spectroscopy is a spectroscopic analysis technique based on molecular vibrational energy level transitions. By detecting the absorption characteristics of infrared light by the sample, it resolves its chemical bond vibrational modes and molecular structural information. The specific detection steps are as follows:

[0215] The purified recombinant collagen solution from Example 1 was freeze-dried to obtain solid sample C4-Y1. The obtained solid sample C4-Y1 was then placed directly on the diamond surface of a Thermo Scientific Nicolet iS50 Fourier transform infrared spectrometer, and uniform pressure was applied to ensure contact. The scanning range was set to 4000-500 cm⁻¹. -1 4cm resolution -1 The number of scans was 64. The humidity in the laboratory was controlled below 30% to avoid water vapor interference (especially at 3300cm). -1 (Near OH peaks). After detection, baseline correction was performed on the original spectrum using instrument software (such as OMNIC) to eliminate background interference. Simultaneously, solid samples of competitor JB-XVII type collagen and standard type III collagen (Sigma) were detected and compared with recombinant type IV collagen C4-Y1. Results are shown in […]. Figure 4 .

[0216] Characteristic peak identification: Mark the characteristic absorption peaks of collagen (such as amide I, II, and III bands) and record the peak positions (cm). -1 Peak strength and half-peak width.

[0217] Collagen characteristic peaks:

[0218] 1. Amide A band: typically located at ~3300cm -1 The peaks are broad and strong, reflecting its highly ordered hydrogen bond network.

[0219] 2. CH stretching vibration (2800-3000cm) -1 ): Symmetric / antisymmetric vibration of aliphatic CH, peak position approximately 2960 cm⁻¹ -1 and 2870cm -1 .

[0220] 3. Amide I band (1600-1700cm) -1 ): Reflects secondary structure (such as α-helix, β-sheet). The triple helix structure of collagen is typically 1650-1660 cm⁻¹. -1 Strong peaks are observed in the vicinity.

[0221] 4. Amide II band (1480-1580cm) -1 The peak is approximately 1550cm. -1 It is often combined with the amide I band to analyze structural changes.

[0222] 5. Amide III band (1200-1300cm) -1 ): Approximately 1240cm -1 It has relatively weak strength and serves as an auxiliary verification structure.

[0223] Depend on Figure 4 It can be seen that recombinant type IV collagen C4-Y1 and its competitor, type JB-XVII collagen, have similar characteristic peaks and wavenumbers, indicating that they have similar structures. Comparison of their infrared spectra with those of the standard Sigma III collagen revealed that both also exhibit similar characteristic peaks, indicating that they have similar structures.

[0224] Example 3: Bioactivity of recombinant humanized type IV collagen

[0225] 1. The role of recombinant type IV collagen C4-Y1 in promoting cell migration.

[0226] Take a 12-well plate and inoculate 0.8 × 10⁸ g of the solution into each well. 6 HaCaT cells were cultured for 16-18 hours, forming a monolayer of 100%-110% density in each well. The cells in each well were scratched with a pipette tip, the scratched cells were washed away, and the appropriate culture medium was added.

[0227] 1 mg / mL C4Y1 group: Mix 250 μL of recombinant type IV collagen C4-Y1 at a concentration of 2 mg / mL with 250 μL of serum-free DMEM medium and add it to one well of a 12-well plate;

[0228] 0.5 mg / mL C4Y1 group: Mix 250 μL of recombinant type IV collagen C4-Y1 at a concentration of 1 mg / mL with 250 μL of serum-free DMEM medium and add it to one well of a 12-well plate;

[0229] 0.25 mg / mL C4Y1 group: Mix 250 μL of recombinant type IV collagen C4-Y1 at a concentration of 0.5 mg / mL with 250 μL of serum-free DMEM medium and add it to one well of a 12-well plate;

[0230] 1 mg / mL C4Y2 group: 250 μL of recombinant type IV collagen C4-Y2 at a concentration of 2 mg / mL was mixed with 250 μL of serum-free DMEM medium and added to one well of a 12-well plate;

[0231] 0.5 mg / mL C4Y2 group: 250 μL of recombinant type IV collagen C4-Y2 with a concentration of 1 mg / mL was mixed with 250 μL of serum-free DMEM medium and added to one well of a 12-well plate;

[0232] 0.25 mg / mL C4Y2 group: 250 μL of recombinant type IV collagen C4-Y2 at a concentration of 0.5 mg / mL was mixed with 250 μL of serum-free DMEM medium and added to one well of a 12-well plate;

[0233] 1 mg / mL Competitor Group 2: Mix 250 μL of 2 mg / mL competitor 2 (natural human type IV collagen (Aladdin C390608-1 mg, the same below) with 250 μL of serum-free DMEM medium and add it to one well of a 12-well plate;

[0234] 1 mg / mL BSA group: Mix 250 μL of 2 mg / mL BSA with 250 μL of serum-free DMEM medium and add it to one well of a 12-well plate; (BSA is bovine serum albumin (BSA) powder dissolved in physiological saline)

[0235] NC group: Mix 250 μL of sterile saline with 250 μL of serum-free DMEM medium and add it to one well of a 12-well plate.

[0236] Take a photo at 0h and calculate the scratch area S0; take a photo at the same location at 12h and calculate the scratch area S1; calculate the cell migration rate based on the change in scratch area.

[0237] Cell migration rate P = (S0 - S1) / S0.

[0238] See results Figure 5 .

[0239] like Figure 5 As shown, compared with the control group (16.67%), the cell migration rate using the C4-Y1 and C4-Y2 collagen of the present invention (49.54% and 35.32%) was significantly increased and higher than that of competitor 2 (31.05%).

[0240] 2. Effects of recombinant type IV collagen C4-Y1 on HSF cell proliferation

[0241] HSF cells (human skin fibroblasts) were seeded into 96-well plates at a density of 3000 cells per well. After culturing for 16-18 hours, a monolayer of cells with a density of 25%-35% was formed in the wells. The original culture medium was discarded, and the cells were divided into four groups: NC group, C4Y1 group, C4Y2 group, competitor group 2, and 5% PBS group. The cells in each group were then treated as follows:

[0242] C4Y1 group: 350 μL of recombinant type IV collagen C4-Y1 with a concentration of 2 mg / mL was mixed with 350 μL of 2% serum medium (HSF special medium: DMEM / F12 (Gibco product number C11330500BT) = 1:4, purchased from Xiamen Yimo Biotechnology Co., Ltd., the same applies below), and 200 μL was added to each well, with 3 replicates.

[0243] C4Y2 group: Mix 350 μL of recombinant type IV collagen C4-Y2 at a concentration of 2 mg / mL with 350 μL of 2% serum culture medium, add 200 μL to each well, and set up 3 replicates;

[0244] Competitor Group 2: Mix 350 μL of competitor 2 (1 mg / mL) with 350 μL of 2% serum culture medium, add 200 μL to each well, and set up 3 replicates;

[0245] 5% FBS group: Mix 350 μL of sterile physiological saline with 350 μL of 10% serum culture medium, add 200 μL to each well, and set 3 replicates;

[0246] NC group: Mix 350 μL of sterile saline with 350 μL of 2% serum culture medium, add 200 μL to each well, and set up 3 replicates;

[0247] After addition, the cells were incubated at 37°C for 72 hours. The protein solution was then discarded, and the cells were washed twice with PBS. Serum-free medium containing 10% CCK8 was added, along with the CCK8 solution in a cell-free blank well. The reaction was carried out at 37°C for 3 hours. The absorbance at 450 nm was measured using a microplate reader, and the relative cell proliferation rate was calculated based on the absorbance.

[0248] Relative cell proliferation rate = (Experimental group A450 - Blank well A450) / (Negative control A450 - Blank well A450).

[0249] See results Figure 6 .

[0250] like Figure 6 As shown, the recombinant type IV collagen C4-Y1 of the present invention has a significantly better effect on HSF cell proliferation than competing product 2.

[0251] 3. Evaluation of the effect of recombinant type IV collagen C4-Y1 on promoting the secretion of Col I and Col III by HSF cells

[0252] In a 12-well cell culture plate, 0.2 × 10⁶ cells were seeded in each well. 6Personal skin fibroblasts (HSF) were cultured at 37°C in a 5% CO2 incubator for 16-18 hours. After the cells reached 90-95% confluence, the original culture medium was discarded, and the cells were divided into four groups: NC group, C4Y1 group, competitor 2 group, and PC group. The cells in each group were then treated as follows:

[0253] C4Y1 group: Mix 250 μL of 2 mg / mL C4-Y1 with 250 μL of complete culture medium (HSF cell culture medium, purchased from Xiamen Yimo Biotechnology Co., Ltd., the same applies below) and add it to a 12-well plate;

[0254] C4Y2 group: Mix 250 μL of 2 mg / mL C4-Y2 with 250 μL of complete culture medium and add to 12-well plates.

[0255] Competitor Group 2: Mix 250 μL of 2 mg / mL competitor 2 with 250 μL of complete culture medium and add it to a 12-well plate;

[0256] NC group: Mix 250 μL of sterile physiological saline with 250 μL of complete culture medium and add it to a 12-well plate;

[0257] After adding the cells, continue culturing for 24 hours. After culturing, collect the cell supernatant from each group and use it separately. A human type I collagen α1 (COL1α1) and type III collagen (COLIII) enzyme-linked immunosorbent assay (ELISA) kit was used to detect ColI and ColIII by ELISA. A standard curve was constructed according to the kit instructions, and the concentrations of ColI and ColIII in the cell culture supernatant of each experimental group and control group were calculated. The significance of differences between groups was analyzed using Graphpad. Results are shown below. Figure 7 .

[0258] like Figure 7 As shown, at the same concentration, the recombinant type IV collagen C4-Y1 of the present invention significantly outperforms competitor 2 at the same concentration in promoting the secretion of ColI by HSF cells; and significantly outperforms competitor 2 at the same concentration in promoting the secretion of ColIII by HSF cells (P<0.0001).

[0259] 4. Effects of different doses of recombinant IV collagen C4-Y1 on intracellular and extracellular ColIII expression in HSF cells

[0260] In a 12-well cell culture plate, 0.2 × 10⁶ cells were seeded in each well. 6Personal skin fibroblasts (HSF) were cultured at 37°C in a 5% CO2 incubator for 16-18 hours until the cells reached 90-95% confluence. The culture medium was then replaced with serum-free medium containing different concentrations (0.16-500 μg / mL) of recombinant type IV collagen C4-Y1. The control (NC) medium was serum-free medium without recombinant type IV collagen C4-Y1. Culture was continued for another 24 hours. After culture, the cell culture supernatant was collected and temporarily stored at 4°C. Intracellular proteins were lysed by adding an equal volume of sterile saline and performing three freeze-thaw cycles at -80°C, followed by centrifugation to collect the supernatant. A human ColIII assay kit was used to detect intracellular and extracellular ColIII protein levels. A standard curve was constructed according to the kit instructions, and the ColIII concentrations in the cell culture supernatant and intracellular cells for each group were calculated. Data were analyzed in GraphPad, and the results are shown below. Figure 8 .

[0261] like Figure 8 As shown, the recombinant IV collagen C4-Y1 of the present invention promotes the expression and secretion of ColIII in HSF cells in a concentration-dependent manner, with an expression level of approximately 10-fold at the highest concentration of 500 μg / mL, and still showing significant differences at a concentration of 0.16 μg / mL (P<0.01).

[0262] 5. Effects of recombinant type IV collagen C4-Y1 on MMP-1 and ColIII transcription levels in HSF cells

[0263] HSF cells were seeded into 12-well plates at a density of 0.2 × 10⁶ cells per well. 6 Cells were cultured until confluence reached 90-95%, then treated with different concentrations of C4-Y1 medium for 12 hours. The medium was discarded, and the cells were washed three times with PBS before total RNA was extracted. RNA was extracted using the EASYspin RNA Extraction Kit, reverse transcribed into cDNA, and then qPCR was performed to detect the relative expression levels of MMP-1 and ColIII RNA in each experimental group and control group. The kits used were: EASYspin Tissue / Cell RNA Rapid Extraction Kit, Thermoscientific RevertAid First Strand cDNA Synthesis Kit, and... Lifesciences Universal Real-Time PCR Kit. Using the NC group as the control group and GAPDH as the internal control, relative quantification of RNA levels in each group was performed. ΔΔ Data analysis was performed using the Ct method. Results are shown below. Figure 9 .

[0264] like Figure 9As shown, the recombinant type IV collagen C4-Y1 of the present invention significantly inhibits MMP-1 gene expression and promotes ColIII transcription, and the effects are significantly better than those of competitor product 2 (P<0.05).

[0265] The above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention in any way. Although the present invention has been disclosed above with reference to preferred embodiments, it is not intended to limit the present invention. Any person skilled in the art can make some modifications or alterations to the methods and techniques disclosed above without departing from the scope of the present invention to create equivalent embodiments. Any simple modifications, equivalent changes and alterations made to the above embodiments based on the technical essence of the present invention without departing from the scope of the present invention shall still fall within the scope of the present invention.

Claims

1. A recombinant humanized collagen type IV, characterized in that, comprises n repeating units, which are connected directly or through a linker, and the repeating unit comprises: (1) an amino acid sequence as set forth in SEQ ID NO. 2; (2) an amino acid sequence obtained by substitution, deletion, or insertion of one or more amino acids based on SEQ ID NO. 2; or (2) an amino acid sequence having at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NO. 2; Preferably, n is an integer from 1 to 20.

2. The recombinant humanized collagen type IV according to claim 1, characterized in that, The collagen comprises: (1) an amino acid sequence as set forth in SEQ ID NO. 1; or (2) an amino acid sequence having at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NO. 1; or (3) an amino acid sequence obtained by substitution, deletion, or insertion of one or more amino acids based on SEQ ID NO.

1.

3. A fusion protein, characterized in that, The fusion protein of claim 3, wherein the recombinant humanized collagen IV comprises n repeating units, which are connected directly or through a linker, and the repeating unit comprises: (1) an amino acid sequence as set forth in SEQ ID NO. 2; or 4. A polynucleotide, characterized in that, (2) an amino acid sequence having at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NO. 2; or (3) an amino acid sequence obtained by substitution, deletion, or insertion of one or more amino acids based on SEQ ID NO.

2.

5. Vector, characterized in that, Preferably, the purification tag is selected from a His tag, a GST tag, a MBP tag, a SUMO tag, or a NusA tag. The fusion protein of claim 3, wherein the recombinant humanized collagen IV comprises n repeating units, which are connected directly or through a linker, and the repeating unit comprises: (1) an amino acid sequence as set forth in SEQ ID NO. 2; or (2) an amino acid sequence having at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NO. 2; or 6. A host cell characterized in that, (3) an amino acid sequence obtained by substitution, deletion, or insertion of one or more amino acids based on SEQ ID NO.

2. Preferably, the polynucleotide comprises a nucleotide sequence as set forth in SEQ ID NO. 5 or a degenerate sequence thereof. The polynucleotide of claim 4, wherein the polynucleotide comprises a nucleotide sequence as set forth in SEQ ID NO. 5 or a degenerate sequence thereof. Preferably, the vector is an expression vector.

7. A method of producing the recombinant humanized collagen type IV according to claim 1 or 2 or the fusion protein according to claim 3, characterized in that, Preferably, the vector comprises a control element operably linked to the polynucleotide. Preferably, the control element is selected from a promoter, a terminator, and / or an enhancer. The polynucleotide of claim 4, or the vector of claim 5. Preferably, the host cell is selected from a bacterium, a fungus, or an animal cell.

8. Composition, characterized in that, Preferably, the bacterium comprises Escherichia coli. Preferably, the fungus comprises a yeast, such as Pichia pastoris. The method of claim 6, wherein the method comprises the following steps: (1) culturing the host cell of claim 6 under suitable culture conditions; (2) harvesting the host cell and / or the culture medium comprising the recombinant humanized collagen IV or the fusion protein; and optionally (3) purifying the recombinant humanized collagen IV or the fusion protein. The method of claim 6, wherein the method comprises one or more of the recombinant humanized collagen IV of claim 1 or 2, the fusion protein of claim 3, the polynucleotide of claim 4, the vector of claim 5, and the host cell of claim 6.

9. The composition of claim 8, wherein, The composition is selected from one or more of a biological dressing, a human bionic material, a plastic and cosmetic material, an organoid culture material, a cardiovascular stent material, a coating material, a tissue injection filling material, an ophthalmic material, a gynecological biomaterial, a nerve repair and regeneration material, a liver tissue material and a blood vessel repair and regeneration material, a 3D printed artificial organ biomaterial, a cosmetic raw material, a pharmaceutical excipient, and a food additive; Preferably, the composition is a surface composition, an injection composition, or an oral composition; Preferably, the composition is a solution, a lyophilized powder, a gel, a sponge, or a fiber form of the composition.

10. Use of the recombinant humanized collagen type IV according to claim 1 or 2, the fusion protein according to claim 3, the polynucleotide according to claim 4, the vector according to claim 5, and the host cell according to claim 6 in the manufacture of one or more of a biological dressing, a human bionic material, a plastic and cosmetic material, an organoid culture material, a cardiovascular stent material, a coating material, a tissue injection filling material, an ophthalmic material, a gynecological biomaterial, a nerve repair and regeneration material, a chronic wound repair material, a bone / cartilage regeneration material, a liver tissue material and a blood vessel repair and regeneration material, a 3D printed artificial organ biomaterial, a cosmetic raw material, a pharmaceutical excipient, and a food additive.

11. A method of promoting cell proliferation, migration or adhesion, characterized in that, comprising the step of contacting a cell with the recombinant humanized collagen type IV according to claim 1 or 2, the fusion protein according to claim 3, the polynucleotide according to claim 4, the vector according to claim 5, the host cell according to claim 6, and / or the composition according to claim 8 or 9; Preferably, the cell is an animal cell; Preferably, the animal cell is a mammalian cell; Preferably, the mammalian cell is a human cell; Preferably, the promoting cell proliferation, migration, or adhesion is performed in vitro.

12. A method of performing a cosmetic, tissue injection filler, ophthalmic treatment, nerve repair, or vascular repair in a subject in need thereof, characterized in that, comprising administering to a subject the recombinant humanized collagen type IV according to claim 1 or 2; Preferably, the administration is oral administration or injection administration; Preferably, the subject is a human.

13. Use of the recombinant humanized collagen type IV according to claim 1 or 2 in the manufacture of a medicament for a disease or disorder associated with collagen type IV deficiency.